Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Last trade$1.40
Day change-$0.055 (-3.79%)
Day range$1.40 – $1.54
Volume432,035
Market cap$203M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$203.39M
Price / earnings
—
Price / book
1.08×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.03×
Profitability
Earnings per share
-$0.49
Return on assets
-34.29%
Return on equity
-36.64%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.34×
Quick ratio
15.34×
Cash ratio
3.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$49.37M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IKT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$7.23M
$7.66M
$7.38M
$6.77M
$5.61M
$5.92M
$5.25M
$5.74M
Research and development
$15M
$13.39M
$10.84M
$6.36M
$7.65M
$5.27M
$10.51M
$7.19M
Total operating expenses
$22.23M
$21.05M
$17.84M
$13.78M
$12.77M
$10.83M
$14.6M
$12.93M
Operating income
-$22.23M
-$21.05M
-$17.84M
-$13.78M
-$12.77M
-$10.83M
-$14.6M
-$12.93M
Interest expense
$0
$0
$0
-$2.67M
$0
$0
$0
-$273.06K
Income before taxes
-$20.47M
-$19.59M
-$16.38M
-$12.73M
-$11.93M
-$9.92M
-$13.68M
-$12.13M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$20.47M
-$19.59M
-$16.38M
-$12.73M
-$11.93M
-$9.92M
-$13.68M
-$12.13M
Net income attributable to common shareholders
-$20.47M
-$19.59M
-$16.38M
-$12.73M
-$11.93M
-$9.92M
-$13.68M
-$12.13M
EBITDA
-$22.23M
-$21.05M
-$17.84M
-$13.78M
-$12.74M
-$10.81M
-$14.59M
-$12.92M
Basic earnings per share
-$0.10
-$0.11
-$0.10
-$0.10
-$0.13
-$0.11
-$0.15
-$0.17
Diluted earnings per share
-$0.10
-$0.11
-$0.10
-$0.10
-$0.13
-$0.11
-$0.15
-$0.17
Recent news
Company coverage with links to the original publishers.
Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.
Inhibikase Therapeutics announced the grant of non-qualified stock options to purchase 685,718 shares to five newly-hired non-executive employees under its 2026 Inducement Equity Plan. The options have an exercise price of $1.68 per share with a ten-year term and a standard vesting schedule of 25% after one year followed by 36 monthly installments.
Inhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.
A Polish credit bureau analysis reveals that including Buy Now Pay Later (BNPL) transaction data in credit histories could help nearly 40% of 'thin-file' bank customers improve their creditworthiness, with BNPL transactions showing high repayment rates and low default risks.
The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.